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Abstract
The B apolipoproteins, apo-B48 and apo-B100, are key struc-
tural proteins in those classes of lipoproteins considered to be
atherogenic [e.g., chylomicron remnants, ,f-VLDL, LDL, oxi-
dized LDL, and Lp(a)J. Here we describe the development of
transgenic mice expressing high levels of human apo-B48 and
apo-B100. A 79.5-kb human genomic DNA fragment contain-
ing the entire human apo-B gene was isolated from a P1 bacte-
riophage library and microinjected into fertilized mouse eggs.
16 transgenic founders expressing human apo-B were gener-
ated, and the animals with the highest expression had plasma
apo-B100 levels nearly as high as those of normolipidemic hu-
mans (- 50 mg/dl). The human apo-B100 in transgenic
mouse plasma was present largely in lipoproteins of the LDL
class as shown by agarose gel electrophoresis, chromatography
on a Superose 6 column, and density gradient ultracentrifuga-
tion. When the human apo-B transgenic founders were crossed
with transgenic mice expressing human apo(a), the offspring
that expressed both transgenes had high plasma levels of hu-
man Lp(a). Both the human apo-B and Lp(a) transgenic mice
will be valuable resources for studying apo-B metabolism and
the role of apo-B and Lp(a) in atherosclerosis. (J. Clin. Invest.
1993. 92:3029-3037.) Key words: P1 bacteriophage - low den-
sity lipoproteins * cholesterol
Introduction
Both B apolipoproteins (apo-B48 and apo-B I 00),' play central
roles in mammalian lipoprotein metabolism (1, 2). apo-B100
is the key structural protein in the formation of triglyceride-
rich VLDL and is virtually the only protein in the cholesteryl
ester-enriched LDL. Epidemiologic (3) and pathologic studies
(4) repeatedly have demonstrated that high plasma levels of
apo-B100 and LDL cholesterol are risk factors for premature
atherosclerosis. Moreover, individuals with genetic disorders
such as familial hypercholesterolemia (5, 6) and familial defec-
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tive apo-B 100 (7-9), which are characterized by high plasma
concentrations of LDL cholesterol, have an increased inci-
dence of premature atherosclerotic disease. apo-B48, the
amino-terminal 48% ofthe full-length apo-B100, is an obligate
structural protein in chylomicron formation in the small intes-
tine. Its synthesis results from the enzymatic editing of a single
nucleotide of the apo-B mRNA (apo-B100 cDNA nucleotide
6666), which converts glutamine-2153 into a stop codon (10-
12). In humans, virtually no apo-B48 is synthesized in the liver
(13). In rats and mice, however, the liver expresses the apo-B
mRNA editing activity (14) and therefore synthesizes both
apo-B48 and apo-B 100. Greeve et al. (15) found that 70% of
mouse hepatic apo-B mRNA is edited. In many mouse strains,
the concentration ofapo-B48 in mouse plasma exceeds that of
apo-B100 (16).
apo-B1100 is an important component of another athero-
genic lipoprotein in human plasma, lipoprotein(a) [Lp(a)].
Lp(a) is formed by the high affinity association of apo-B100
LDL with apo(a) (17, 18). The interaction between apo-B100
and apo(a) is assumed to involve an intermolecular disulfide
bond between apo(a) and one ofthe carboxyterminal cysteines
of human apo-B100, although the existence of the disulfide
bond and its location within the apo-B100 sequence have yet to
be definitively established (19-22). In transgenic mice express-
ing human apo(a) (21), the apo(a) circulates free in the
plasma rather than associating with murine lipoproteins. Infu-
sion ofhuman LDL into the apo(a) transgenic mice resulted in
the rapid association of the apo(a) with the human lipopro-
teins. Based on these studies, it is presumed that human apo(a)
fails to associate with mouse apo-B100 due to primary struc-
tural differences between mouse and human apo-B. It would be
predicted that transgenic mice expressing both apo-B100 and
apo(a) would form human Lp(a).
To study the role of apo-B100 in lipoprotein metabolism
and the role of apo-B100 and Lp(a) in atherogenesis, we have
developed transgenic mice expressing human apo-B 100
and Lp(a).
Methods
Generation ofhuman apo-B transgenic mice. Oligonucleotides B 1 (5'-
GAA GAA CTT CCG GAG AGT TGC AAT-3') and B2 (5'-CTC
TTA GCC CCA TTC AGC TCT GAC-3') were used to amplify a
300-bp fragment located 4543-4244 bp 5' of the apo-B transcriptional
start site; oligonucleotides B3 (5'-CGG AAG GTC TCT GAA CTC
AGA AG-3') and B4 (5'-CCC TCC ATA ATT TCT CCG TTT CCA-
3') were used to amplify a 261 -bp fragment located 179 bp downstream
from the TAA stop codon in exon 29 ofthe apo-B gene. After optimiza-
tion of the enzymatic amplification conditions, the oligonucleotides
were sent to Genome Systems, Inc. (St. Louis, MO) for PCR screening
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ofa human genomic DNA library constructed in the bacteriophage P1
(23). A single P1 clone (Dupont Merck Pharmaceutical Company-
Human Foresk in Fibroblast [DMPC-HFF] no. 1-261G, here desig-
nated p 158) yielded positive PCRs with both sets ofprimers. The iden-
tity ofclone p158 was confirmed by PCRs using apo-B-specific oligonu-
cleotides from various regions of the apo-B gene (24, 25). Automated
DNA sequencing was used to verify the nucleotide sequence of 5,424
bp ofclone p158, including a large portion ofapo-B exons 26 and 29. In
addition, p158 and pSV2neo were cotransfected into a rat hepatoma
cell line, and human apo-B100-secreting stable transformants were ob-
tained (M. Linton and S. Young, unpublished observations).
To prepare p158 DNA for microinjection, p158 DNA was isolated
from the NS3529 strain ofEscherichia coli by alkaline lysis, purified by
CsC12 ultracentrifugation (26), and then cleaved with NruI. The cut
DNA was subjected to electrophoresis on a 0.8% agarose gel, and the
79.5-kb band containing the apo-B gene was electroeluted into 0.5%
TBE; the fragment was then repurified on a CsCl2 gradient (27). The
CsCl2 fractions containing the 79.5-kb NruI fragment were pooled,
dialyzed against microinjection buffer (27), adjusted to a concentra-
tion of 3 ng/,l, and then microinjected into 120 fertilized ICR eggs at
the Gladstone Institutes (San Francisco, CA). The sameDNA prepara-
tion also was microinjected into 185 and 59 (C57BL/6J x SJL) F.
fertilized eggs at DNX Biotherapeutics, Inc. (Princeton, NJ) and the
University of Texas Southwestern Medical Center at Dallas, respec-
tively.
Transgenic animals were identified by Southern blot or dot blot
analysis oftail DNA using a 32P-labeled human apo-B probe. Founders
that expressed human apo-B were mated with ICR, C57BL/6J, or
(C57BL/67 X SJL) F. mice, and the transgenic offspring were identi-
fied by a specific human apo-B radioimmunoassay (see below). All
mice were fed a normal chow diet.
RNA slot blot studies. Total cellular RNA was isolated as previously
described (28) from tissues of a 5-wk-old transgenic offspring of
founderM 1I and one nontransgenic littermate. The slot blot studies of
apo-B mRNA expression were performed as previously described (26).
Three amounts of total cellular RNA (4, 1, and 0.25 Mg) were loaded
onto a sheet ofnitrocellulose membrane using a slot blot apparatus and
then probed with a 32P-labeled human apo-B-specific cDNA probe
(apo-B cDNA nucleotides 7335-10068) as well as a 3.7-kb EcoRI frag-
ment ofthe apo-B gene extending from intron 24 to cDNA nucleotide
6507 within exon 26. The membrane was washed at high stringency
(26) and autoradiography was performed.
Determination oftransgene copy number. For founders 1-11, tail
DNA was prepared as described (29), digested with HindIII, and sub-
jected to electrophoresis on 0.8% agarose gels. After transfer to nylon
membranes, the blots were hybridized simultaneously with 32P-labeled
probes from exon 26 ofthe human apo-B gene and exon 25-intron 25
of the mouse apo-B gene. Copy number was quantitated using a Fujix
phosphoimager (BAS1000; Fuji, Stamford, CT). For founders 12-16,
copy number was quantitated using dot blot analysis and a phospho-
imager (Molecular Dynamics, Inc., Sunnyvale, CA).
Human apo-BJOO RIAs. To assess the amount ofhuman apo-B in
mouse plasma samples, two different mAb-based RIAs for human apo-
B100, similar to those described previously (30-33), were used. The
first RIA, a very sensitive, direct-binding "sandwich RIA" using two
different human apo-B-specific mAbs, was used to identify transgenic
founders and their transgenic offspring, and to assess the relative
amounts of human apo-B100 in fractions from density gradients or
Superose 6 chromatography. For this assay, flexible polyvinyl chloride
96-well plates were coated for 4 h at 4°C with 50 Al ofPBS containing 2
Mg/ml of immunopurified mAb MB47 (30). (Antibody MB47 binds
near human apo-B100 residue 3500 [34] and therefore does not bind
to apo-B48.) The plates were washed four times with PBS containing
0.1% RIA-grade bovine serum albumin, 0.05% Tween 20, and 0.04%
sodium azide (SPRIA) and incubated with SPRIA containing 2% BSA
(SPRIA-BSA) for I h at 20°C to block nonspecific binding sites. To test
for the presence of human apo-B100, samples (aliquots of mouse
plasma, Superose 6 chromatography fractions, or density gradient frac-
tions) were diluted in SPRIA-BSA, added in triplicate to the 96-well
plate, and incubated overnight at 40C. The plates were washed six
times with SPRIA. Then, 50 M1 of SPRIA-BSA-containing '25I-labeled
human apo-B-specific mAb CA.4 (35) (8,000 cpm/Mgl), which binds
near apo-B 100 amino acid 500, was added to each well and incubated
at 4VC for 4 h. (Antibody CI.4, which was generously provided by E.
Krul ofWashington University [St. Louis, MO] was radiolabeled using
the lactoperoxidase method [BioRad, Richmond, CA] to a specific
activity of -10,000 cpm/ng). The plates were washed again with
SPRIA and individual wells counted. Because the RIA was quite sensi-
tive, detecting as little as 0.3 ng of human apo-B100 per well, it was
capable ofmeasuring relative amounts ofapo-B 100 in density fractions
and Superose 6 chromatography fractions. It also was useful for deter-
mining whether a mouse expressed human apo-B since 1 Ml of trans-
genic mouse plasma (even from mice with very low apo-B expression
levels) typically yielded > 20,000-30,000 cpm in this assay, whereas 1
Ml of nontransgenic plasma yielded a background of only 200-300
cpm. This RIA was not useful, however, for measuring the human
apo-B100 content of transgenic mouse plasma because the binding
curves for dilutions of human plasma and mouse plasma were not
parallel.
A second competitive RIA was used to measure the human apo-
B100 concentration in transgenic mice. Antibody MB47-coated 96-
well plates were prepared as described above. Serial dilutions ofhuman
and transgenic mouse plasma were prepared in 25 Ml of SPRIA and
pipetted into the MB47-coated wells. Then, a total of 25 Mil of a fixed
concentration of 1251I-human LDL (6,000 cpm/Ml) was added to each
well. The human LDL sample was prepared by sequential ultracentrifu-
gation and radioiodinated using the lactoperoxidase method to a spe-
cific activity of 5,000-10,000 cpm/ng. The 96-well plates were incu-
bated overnight at 4°C, washed six times with SPRIA, and individual
wells counted. Competition curves were plotted on semilog graph
paper as B/Bo vs. the log ofthe Ml ofplasma added to each well, whereB
and Bo represent the cpm bound in the presence and absence ofcompet-
itor, respectively. The competition curves for human apo-B100 in hu-
man and transgenic mouse plasma were invariably parallel. The
amount of human apo-B in mouse plasma samples was determined
using a human plasma secondary standard and a linear regression of
logit B/B0 vs. the log of the standard concentration. The apo-B 100
concentration of the secondary standard was 55 mg/dl, as judged by
competitive RIA (32). The standard was stored at -70°F and used
within 6 wks of the phlebotomy.
Lipoprotein separation and analysis. Blood was taken from the tail
or retroorbital plexus ofmice during the light cycle, and the plasma was
isolated after centrifugation at 14,000 rpm in a microcentrifuge for 10
min at 4°C. In some experiments, phenylmethylsulfonyl fluoride (final
concentration, 1 mM) was added to the plasma samples. Plasma sam-
ples (50-100 Ml) from individual mice were chromatographed on a
Superose 6 10/50 column (Pharmacia Fine Chemicals, Piscataway,
NJ) equilibrated with PBS, and the column was eluted at a flow rate of
0.5 ml/min. 55 fractions (0.5 ml each) were collected. Cholesterol and
triglycerides were measured by a colorimetric method on a I00-M1 sam-
ple of each 500-Ml Superose 6 fraction (36).
Sequential ultracentrifugation of human and mouse plasma sam-
ples ( 100-150 Ml) was used to isolate the VLDL (d < 1.006 g/ml),
intermediate density lipoproteins (d = 1.006-1.019 g/ml), LDL (d
= 1.019-1.063 g/ml), and HDL (d = 1.063-1.21 g/ml) in a tabletop
centrifuge (TL-100; Beckman Instrs., Inc., Fullerton, CA) for 2.5 h at
100,000 rpm, 10°C. After dialysis against a 0.9% NaCl, 1 mM EDTA
solution (pH 7.4), each fraction was assayed to determine its choles-
terol, triglycerides, and phospholipid content. The cholesteryl ester
content of each fraction was determined by subtracting the free choles-
terol, measured with a kit (Free Cholesterol C; Wako, Osaka, Japan),
from the total cholesterol, determined by an enzymatic method (Boeh-
ringer Mannheim Biochemicals, Indianapolis, IN).
Electrophoresis of plasma samples and lipoprotein fractions was
performed using 1% agarose gels as previously described (31). The gels
either were dried and stained for lipid with Fat red 7B, or the proteins
were transferred to a nitrocellulose membrane and immunoblotted
(3 1 ) with 125I-labeled antibody C1.4 or a rabbit antiserum to rat apo-B
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(generously provided by R. Davis, San Diego State University, San
Diego, CA). To insure that the rat antiserum would not detect human
apo-B, 2 ml of the antiserum was passed over a 4-ml human LDL-Se-
pharose 4B column (prepared with cyanogen bromide-activated Seph-
arose 4B according to the manufacturer's instructions; Pharmacia,
Uppsala, Sweden). The IgG was purified from the antiserum on an
ImmunoPure (G) IgG Purification Kit (Pierce, Rockford, IL) accord-
ing to the manufacturer's instructions and then radioiodinated using
the lactoperoxidase method.
To assess the relative amounts ofhuman apo-B48 and apo-B 100 in
the transgenic mouse plasma, 1-2 Ml ofmouse plasma was size fraction-
ated on 3-12% SDS-polyacrylamide slab gels as previously described
(37). The separated proteins were then electrophoretically transferred
to polyvinylidene difluoride membrane (Imobilon-P; Millipore, Bed-
ford, MA) in (3-[cyclohexylamino]-1-propanesulfonic acid) (CAPS)
buffer ( 10 mM CAPS, 10% methanol, pH 1 1 ) at 150 mA for 16 h or
300 mA for 4 h. Immunoblots were performed using '25I-labeled anti-
bodies MB47 or C1.4 as previously described (30, 37). To quantitate
the relative amounts of apo-B48 and apo-B100 in mouse plasma, the
antibody C1.4 immunoblots were then scanned using a gel scanner
(AMBIS, Inc., San Diego, CA).
Analysis ofapo(a) distribution in transgenic mouse plasma. The
human apo-B100 transgene founder 620-1 (see Table I) was bred with
a male mouse hemizygous for the human apo(a) transgene (21). The
resulting litter of six mice was screened for human apo-B expression in
the plasma by Western blotting using mAb MB3 (31, 38). To evaluate
the presence ofhuman apo(a) in the mouse plasma and to determine if
the apo(a) circulated freely or bound to lipoproteins, 1 M1 of mouse
plasma was loaded onto a 4% nondenaturing polyacrylamide gel and
immunoblotted as described previously (21 ) using a mAb specific for
human apo(a), IgG-IA2, conjugated to horseradish peroxidase.
Results
A map of the P1 bacteriophage clone containing the entire
apo-B gene is shown in Fig. 1 A. The P1 DNA was cleaved with
NruI, yielding a 79.5-kb insert containing < 550 bp of vector
sequences. The fragment contained the entire coding region of
the apo-B gene as well as 19 kb of 5' flanking sequences and
17.5 kb of sequences 3' to the gene. The purified 79.5-kb DNA
fragment was microinjected into fertilized murine eggs in three
laboratories, and 16 transgenic founders expressing human
apo-B were obtained (Table I). The DNA of each of the
founders was analyzed to determine the approximate transgene
copy number by Southern blot or dot blot analysis (Fig. 1 B
and Table I). The human apo-B100 plasma levels of these
founders, as measured by competitive RIA, ranged from 0.8 to
50.7 mg/dl (Table I). In addition to the 16 founders expressing
human apo-B in their plasma, 4 transgenic animals were iden-
tified that did not express apo-B in the plasma.
A competitive RIA demonstrating the ability of several
transgenic plasma samples to compete with '251-human LDL
for binding to immobilized antibody MB47 is shown in Fig. 2.
The plasma from one of the transgenic founders (founder
1102) was equally effective in competing with '25I-LDL for
binding to antibody MB47 as the plasma from a normolipid-
emic human subject. The plasma from the other two transgenic
mice (621-1 and 1 101 ) were slightly less effective competitors.
Of note, the displacement curves for human and transgenic
mouse plasma were parallel, indicating that the epitope for
antibody MB47 is expressed similarly in the lipoproteins of
human and transgenic mouse plasma.
To determine the tissue distribution of human apo-B ex-
pression, an RNA slot blot assay using tissue from one trans-
genic and one nontransgenic offspring of founder M 1I was
performed. The human apo-B mRNA was present largely in
liver (Fig. 3). On a much longer exposure, very small amounts
of expression could be detected in small intestine and heart.
To quantify the relative amounts of human apo-B 100 and
A Figure 1. Map of the P1 bacterio-
X X phage clone containing the human
S B K BKK N K BB BrS B l B C K BN apo-Bgene(A)andaSouthernblotI II Il I LrC i _ I l I analysis ofhuman apo-B transgenicii>l II ,ii I * ,- | |,mice(B). The P1 clone, p158,
Insert of p158:79.5kb H H which was mapped by restriction
6J
- ,endonuclease digestion of plasmid
^^ p^robe ,,,, DNA, extends 19 kb 5' to the tran-
scriptional start site and 17.5 kb 3'
" S Nr NrN of the polyadenylation site. S, Sall;%'%f' B, BamHI; K, KpnI; X, XhoI; C,
plasmid:16.8 kb Clal; N, NotI; Nr, NruI. Approxi-
mately three BamHI and three KpnI
sites, located in the far 5' and 3' re-
gions of the insert, are not indicated
B because they remain unmapped.NruI cleaves the plasmid 370 and
1
175 bp, respectively, from the poly-
8.1 kb * - linker Sal and Notl sites. Genomic(u
5. ,it* * DNA was extracted from the tail of
V IIXthe founder mice and digested with
2.7 kb HindIlI; Southern blots were probed(human)
. simultaneously with a 2,733-bp
HindlIl fragment from human exon
1 2 3 4 5 6 7 8 91011 26 and a 700-bp exon 25-intron 25
fragment from the mouse apo-B
gene (B). The mouse probe detects an 8.1-kb HindIl fragment that includes almost all of mouse exon 26, and the human probe detects a 2,733
bp fragment. Lane I shows DNA from the human hepatoblastoma cell line HepG2; lanes 2-9 include founders that express apo-B in plasma
(M3, M6, Ml 1, MiS, 1095, 1097, 1101, and 1102, respectively). Lane 10 contains a sample from a founder that expressed no human apo-B 100
in the plasma; lane 11 shows DNA from a nontransgenic mouse. The band between the mouse apo-B band and the human apo-B band is most
likely a human apo-B gene fragment resulting from a partial HindlII digestion of the genomic DNA.
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Table I. Human Apo-B Transgenic Mouse Founders
Transgenic Transgene copy Human
founders* Sex numbert Apo-B1O($ Chol TG
mg/dl
1.M3 F 1 1.9 117 80
2. M6"1 F 3 1.5 68 174
3. Ml " M 3 5.9 126 140
4. M1511 F 4 6.8 136 202
5. M44 F 6 12.1 146 114
6. M45 F 3 3.8 199 85
7. 620-1"1 F 42 28.3 143 224
8. 620-2' F 17 4.4 97 172
9.621-111 F 25 41.1 175 207
10. 621-2 F 7 10.2 109 196
11. 621-6"1 M 6 11.2 130 182
12. 1095"1 F 1 0.8 99 133
13. 109711 M 3 2.8 133 360
14. 1099 M 1 0.9 113 229
15. 1101 F 9 31.8 155 195
16. 110211 F 10 50.8 164 116
Chol, total plasma cholesterol; TG, triglycerides. * Founders 1-6 are
ICR mice generated in San Francisco, CA; founders 7-11 are C57
x SJL mice generated in Dallas, TX; founders 12-16 are C57 X SJL
mice generated in Princeton, NJ. $ Transgene copy numbers for
animals 1-6 and 12-16 were determined from Southern blots; for
animals 7-1 1, copy number was determined from a slot blot.
§ Competitive RIA for human apo-B measures only human apo-B100,
not human apo-B48. Ii Transmission of transgene to offspring docu-
mented. 'Animal died.
apo-B48 in transgenic mouse plasma, plasma samples were
subjected to size fractionation on 3-12% SDS-polyacrylamide
gels, and Western blots were performed using the human apo-
B-specific mAb CA.4. The Western blots revealed that apo-
B100 was the predominant species of human apo-B in the
plasma of two founders expressing large amounts of human
apo-B, 1101 and 1102 (Fig. 4 A, lanes 4 and 5); gel scanning
revealed that human apo-B1OO/apo-B48 ratios in these mice
were 3.7 and 5.4, respectively. Plasma from mice expressing
lower plasma levels ofapo-B 100 had lower apo-B 100/apo-B48
ratios: 0.09 in M 1I and 1.0 in 1097 (Fig. 4 A, lanes 2 and 3).
The plasma cholesterol levels in the transgenic mice ex-
pressing high levels ofhuman apo-B were higher than those of
nontransgenic mice. For transgenic founders 7-1 1 and 12-16
(Table I), plasma lipid data were compared with data from
nontransgenic littermates. The mean plasma cholesterol level
in founders 7-11 was 130±31 mg/dl vs. 97± 12 mg/dl in six
nontransgenic littermates (P = 0.033). The mean plasma tri-
glyceride level in founders 7-11 was 197±20 vs. 128±20 in the
seven nontransgenic controls (P < 0.001). The mean plasma
cholesterol level in founders 12-16 was 132±27 mg/dl vs.
71 ± 15 mg/dl in five nontransgenic littermates (P = 0.002).
For the ICR founders 1-6, the plasma apo-B levels did not
correlate well with the total plasma cholesterol levels. This is
probably due to the diverse genetic backgroundand cholesterol
levels in this outbred strain, and due to the relatively low
plasma human apo-B levels in these founders.
Founder 1102 was crossed with a C57BL/6J male, and
°o 0.
0.5 0
0.4-
0.3-
0.2-
0.1
000.0082 0.0185 0.055 0.168 0.5
pi of plasma added per well
Figure 2. Competitive RIA of human and transgenic mouse plasma.
The RIA was performed as described in Methods. Briefly, human or
transgenic mouse plasma (from 0.0061 to 0.5 ll) were diluted in 25
,d of SPRIA-BSA and added to the 96-well plates. Then, 25 Ml of a
fixed concentration of 1251I-human LDL (diluted in SPRIA-BSA) was
added to each well, and the plates were incubated overnight at 4VC.
The plates then were washed and individual wells counted. The hu-
man plasma sample used in this experiment had a total cholesterol
level of 165 mg/dl, an LDL cholesterol level of 100 mg/dl, and an
apo-B100 level of 55 mg/dl. (o----o) Human plasma; (rn-)
founder 1101; (.*- ) founder 1102; (A-A) founder 621-1;
(o -o ) a nontransgenic offspring of founder 1 102.
x SJL) F1 males. The plasma lipids were analyzed in their
transgenic and nontransgenic offspring. Founder 1102, the
highest expresser, had nine offspring, four of which were trans-
genic and had human apo-B100 levels equivalent to those in
the founder (Fig. 5 C). The mean cholesterol level in the trans-
genic offspring was 1 10±8 vs. 66±9 mg/dl in the five nontrans-
genic littermates (P < 0.001 ) (Table II). The mean triglyceride
level in the four transgenic mice was 152±10 vs. 102±1 1 mg/dl
in the nontransgenic littermates (P < 0.001). A statistically
significant difference in the plasma cholesterol level was also
observed in the transgenic and nontransgenic offspring of
founders 620-1 and 621-1 (Table II). The triglyceride level was
higher in the transgenic offspring of 620-1 and 621-1, but the
0.25pg 1 pg 4pg
.ED4n
Uo
c
a
co
2
0
z
founders 620-1 and 621-1 were crossed with (C57BL/6J
- Liver
- Small Intestine
- Kidney
- Spleen
- Heart
- Brain
- Liver
- Small Intestine
- Kidney
- Spleen
- Heart
- Brain
] 2HepG2 cells
-
- HepG2 cells
(G8)
Figure 3. Slot blot analysis
ofthe tissues sites ofhuman
apo-B mRNA expression
in a 5-wk-old transgenic
mouse and a nontransgenic
littermate. Positive controls
include two different RNA
preparations from HepG2
cells and one RNA prepa-
ration from a HepG2 cell
clone (G8) in which one of
the apo-B alleles had been
inactivated by gene target-
ing techniques (53).
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.
Apo-BTransgenics Human Plasma
Nontransgenic
Figure 4. Immunoblot analysis of plasma from apo-B transgenic
mice. A total of 2 pi of mouse plasma was size fractionated on 3-12%
SDS-polyacrylamide gels, and the separated proteins were then elec-
trophoretically transferred to a sheet of Immobilon-P membrane for
Western blots. (A) Antibody C1.4 immunoblot. Antibody C 1.4 binds
near apo-B 100 amino acid 500 (35). Lane 1, plasma from founder
1095; lane 2, founder Ml 1; lane 3, founder 1097; lane 4, founder
1101; lane 5, founder 1102; lane 6, nontransgenic mouse plasma;
lane 7, plasma taken from a human subject after a fat-rich meal. The
exposure for lane I was 4 d; for all other lanes, it was 16 h. (B) Blot
using an '251I-labeled human apo-B100-specific mAb, MB47. Lane 1,
plasma from founder 1 101; lane 2, from founder 1 102; lane 3, from
a nontransgenic mouse; lane 4, from a human subject.
difference was not statistically significant (Table II). When all
of the offspring of 620-1 and 621-1 were analyzed as a single
group, however, the higher level oftriglycerides in the transgen-
ics achieved statistical significance (P = 0.045).
To determine the lipoprotein distribution of the human
apo-B100 in the plasma ofthe transgenic mice, plasma samples
from selected founder mice and their offspring were analyzed
by agarose gel electrophoresis (Fig. 5). In the plasma of the
high expressing transgenic mice, the amount of (-migrating
lipoproteins increased dramatically (Fig. 5 A, lanes 3 and 4).
By Western blot analysis, the vast majority ofthe human apo-B
was (3 migrating (Fig. 5 B). The four transgenic offspring of
founder 1 102 also had intense j3 bands upon lipoprotein electro-
phoresis (Fig. 5 C).
The analysis ofmouse apo-B expression in the human apo-
B transgenic mice was performed with Western blots ofagarose
gels using a rabbit antiserum to rat apo-B that had been passed
over a human LDL-Sepharose 4B column. An '25I-labeled IgG
fraction did not bind to human apo-B in human plasma, but
detected mouse apo-B in all of the mouse samples (Fig. 6). In
human apo-B transgenic mice, the mouse apo-B levels, as
judged from the Western blot, were not decreased, and possibly
were slightly increased (see Fig. 6, lanes 3 and 4) when com-
pared with levels in nontransgenic littermates.
To determine the cholesterol, triglyceride, and human apo-
B 100 distributions among the various lipoprotein fractions, the
plasma of transgenic and nontransgenic mice was analyzed by
chromatography on Superose 6 columns (Fig. 7). Two of the
high expresser transgenic mice (founders 1 101 and 1 102) had
large LDL cholesterol peaks (chromatography fractions 22-
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Figure 5. Agarose gel electrophoresis of plasma lipoproteins from a
human subject and transgenic and nontransgenic mice. (A) Agarose
gel stained for neutral lipids with Fat red 7B. Lane 1, the plasma of
founder 1095; lane 2, founder 1097; lane 3, founder 1 101; lane 4,
founder 1102; lanes 5-7, nontransgenic littermates; lane 8, normoli-
pidemic human subject. (B) '251-labeled antibody CA.4 Western blot
of an agarose gel. Lanes 1-8 are identical to those shown in A. For
lane 1, a 22-h exposure was used; for the other lanes, a 5-h exposure.
(C) Lipid-stained agarose gel of plasma samples from the nine off-
spring of founder 1 102. Lanes 1, 3, 6, and 9 show plasma samples of
offspring that, by RIA, had human apo-B100 levels identical to
founder 1102. Lanes 2, 4, 5, 7, and 8 show plasma samples from
nontransgenic littermates.
27) that were nearly as tall and somewhat wider than their
respective HDL cholesterol peaks (Fig. 7 A). A triglyceride
peak was present in the LDL fractions (Fig. 7 B) ofthese mice,
but appeared somewhat diminished in the VLDL-sized frac-
tions compared with nontransgenic mice. By solid phase RIA,
the vast majority of the human apo-B100 resided within the
LDL fractions (Fig. 7 C). Discontinuous salt density gradient
ultracentrifugation confirmed that most of the human apo-
B100 within the transgenic plasma of both high and low ex-
pressers was contained in the LDL density range, very similar
to the distribution of LDL in the plasma of a human subject
(Fig. 8).
The VLDL, IDL, LDL, and HDL fractions of founders
12-16 and five nontransgenic littermates were isolated by se-
quential ultracentrifugation. On lipid-stained agarose gels, the
LDL fraction contained largely Emigrating lipoproteins, with
a small amount of a-migrating lipoproteins; the HDL fraction
contained both a- and (-migrating lipoproteins (data not
shown). In two high-expresser founders, 1 101 and 1 102, the
amount of cholesterol in the LDL fraction was 18-fold greater
than in the nontransgenic mice. In founders 1101 and 1 102,
the cholesterol/triglyceride ratios in the LDL fraction were
0.75 and 2.04, respectively.
Human Apolipoprotein BJOO Transgenic Mice 3033
I-
6*-#* lqt
Im
2
I
LO
N
T-
Table I. Lipid Measurements in Offspring of Three Transgenic
Founders Expressing High Levels ofHuman apo-B100
Offspring Cholesterol Triglycerides
mg/dl
1102
Transgenic (n = 4) 110±8 152±10
Nontransgenic (n = 5) 66±9 102±11
(P < 0.001) (P < 0.001)
620-1
Transgenic (n = 2) 109±2 177±18
Nontransgenic (n = 4) 82±9 146±27
(P= 0.015) (P= 0.21)
621-1
Transgenic (n = 3) 146±8 195±69
Nontransgenic (n = 3) 82± 13 135±8
(P = 0.002) (P = 0.20)
Mean±SD are shown.
To determine whether coexpression of human apo (a) and
human apo-B results in the formation of human Lp(a) in the
plasma, a female human apo-B transgenic mouse (620-1 ) was
crossed with a male mouse that was hemizygous for the human
apo(a) transgene (line 275-4). Plasma from the six offspring
were screened for the presence of both human apo-B and
apo(a) by Western blot analysis. In addition, aliquots of
plasma from each of the offspring were loaded onto a 4% non-
denaturing polyacrylamide gel and immunoblotted using the
human apo(a)-specific mAb, 1A2 (Fig. 9). This method was
shown previously to separate free apo(a) from lipoprotein-
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Figure 6. Agarose gel electrophoresis of the plasma lipoproteins of a
human subject and transgenic and nontransgenic mice. (A) Lipid-
stained agarose gel, and (B) Western blot using an '25I-labeled IgG
specific for rat apo-B. For both panels, lane 1, founder 1095; lane 2,
founder 1097; lane 3, founder 1101; lane 4, founder 1102; lanes 5-7,
nontransgenic littermates; lane 8, plasma from a normolipidemic
human subject. In the high expressers (1101 and 1102), the mouse
apo-B was found largely in the ft position.
bound apo(a) (21). In the offspring expressing only apo(a)
(Fig. 9, lane 4), the apo(a) migrated much further into the gel,
to a level identical to the apo(a) from an apo(a)-transgenic
mouse control. In the plasma oftwo mice expressing both hu-
man apo(a) and apo-B (lanes 5 and 6), the apo(a) migrated
only a short distance into the gel, to the same level as human
Lp(a), indicating that the apo(a) was now associated with li-
poproteins. In the offspring, the intensity ofthe apo(a) immu-
noreactive material was greater in the plasma of the apo(a)
X apo-B mice (lanes 5 and 6) than in the mouse expressing
only apo(a) (lane 4). This difference was not simply an artifact
due to variation in the immunoreactivity of free vs. lipopro-
tein-associated apo(a). Immunoblot analysis of reduced and
denatured plasma samples from two sets of offspring disclosed
significantly more apo(a) immunoreactive material in the
apo (a) X apo-B mice than the mice expressing only apo(a) (H.
Hobbs, unpublished observations).
Discussion
In this study, we used DNA from a P1 bacteriophage clone that
contained the entire human apo-B gene to generate transgenic
mice expressing human apo-B48 and apo-B100. 16 founders
were obtained that expressed a wide range of plasma concen-
trations of apo-B1OO, from 0.8 to 50.7 mg/dl. In many of the
founders, the level of human apo-B100 greatly exceeded the
normal apo-B levels in mice, which are - 3.5 mg/dl in
C57BL/6J and SJL mice (16). The human apo-B mRNA was
expressed in high levels in the liver. High levels ofexpression of
the human apo-B transgene completely transformed the lipo-
protein pattern of the mouse from one having extremely low
levels ofLDL cholesterol to one having a large amount ofLDL
cholesterol. The animals expressing large amounts of apo-B
had a "human-like" pattern upon agarose gel electrophoresis,
with an intense ,B band, corresponding to 13-migrating LDL,
and they had large human apo-B100 and LDL cholesterol
peaks by chromatographic analysis ofthe plasma. These trans-
genic mice had significantly higher total plasma cholesterol lev-
els than nontransgenic littermates, and the increase in choles-
terol levels was due to increased cholesterol in the LDL frac-
tion. In addition to markedly increased levels of LDL
cholesterol, there was also a statistically significant increase in
the plasma triglycerides in the transgenic mice, which was asso-
ciated with the presence of triglyceride-rich LDL particles.
The high levels of human apo-B100 in transgenic mouse
plasma are most likely the consequence of both a high rate of
human apo-B100 synthesis and a slow catabolism of human
apo-B100-containing particles. High levels of human apo-B
mRNA in transgenic liver undoubtedly result in high levels of
human apo-B synthesis and secretion. In addition to increased
synthesis, the human apo-B100-containing LDL in the trans-
genic mice may not be cleared rapidly from the circulation; in
vitro binding studies using mouse fibroblasts have demon-
strated that human apo-B100 binds poorly to the mouse LDL
receptor (39). Thus, retarded clearance of human apo-B100
from transgenic mouse plasma may play a role in the high
plasma concentrations of human apo-B 100.
The human apo-B-transgenic mice display a different phe-
notype than a mouse line lacking the LDL receptor described
by Ishibashi et al. (40); on a normal diet, mice homozygous for
the LDL receptor deficiency had a significant accumulation of
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Figure 7. Superose 6 chromatography studies demonstrating the distribution of cholesterol (A), triglycerides (B), and human apo-B100 (C) in
transgenic mouse and nontransgenic samples. The Superose 6 chromatographic analysis ofplasma was performed as described in Methods (36,
54). Cholesterol and triglycerides were measured enzymatically, and the human apo-B100 content was assessed by the direct-binding sandwich
RIA described in Methods. Fractions 16-21 contain VLDL-sized lipoproteins; fractions 22-27, LDL-sized lipoproteins; fractions 28-34, HDL-
sized lipoproteins. (A and B) ( 0 ) Average values for five separate chromatography studies of the plasma of five nontransgenic littermates
of founders 1101 and 1102. (A-C) (. ) Founder 1101 and ( *) founder 1102. (C) (+ --- + ) Distribution of human apo-B 100 in the
plasma of founder 1097. The Superose 6 chromatography fractions from founder 1102 were subjected to electrophoresis on 3-12% SDS-poly-
acrylamide gels, and a Western blot was performed using '251I-antibody CI.4. Apo-B100 was visible in fractions 22-27, with a peak in fractions
23-26. Apo-B48 was visible in fractions 21-33, without a distinct peak in any of the fractions (data not shown).
cholesterol and apo-B100 in the IDL and LDL fractions. This
pattern contrasts with the human apo-B 100 distribution in our
high-expressing transgenic mice, which was confined almost
exclusively to the LDL density fraction. The difference in the
phenotypes ofthe two mice probably relates to the fact that the
LDL receptor plays an important role in the apo-E-mediated
clearance of IDL. The clearance of IDL is undoubtedly defec-
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Figure 8. Density distribution of human apo-B100 in transgenic
mouse plasma and human plasma. Discontinuous salt gradient ultra-
centrifugation ofmouse and human plasma samples was performed
as described in Methods. After ultracentrifugation, the salt gradients
were unloaded into 19 fractions of 280 j1; the apo-B 100 content of
each fraction was assessed in duplicate using the sandwich RIA de-
scribed in Methods. In this figure, the average 1251 cpm for each of
the 19 fractions is plotted against density. (o--- o) Distribution of
human apo-B100 in founder Ml 1 (25 Ml of plasma initially loaded
onto gradient); (- ) founder 1102 (15 ul of plasma loaded);
(a o) normal human plasma (25 ,l of plasma loaded).
tive in the LDL receptor-knockout mice, whereas it may be
relatively normal in the human apo-B-transgenic mice.
In the human apo-B-transgenic mice, it is noteworthy that
the LDL was enriched in triglycerides, a finding that contrasts
with LDL from human plasma, which contains only small
amounts of triglycerides (1). A likely explanation for the in-
creased triglyceride content ofthe transgenic LDL is that mice,
unlike humans, lack cholesteryl ester transfer protein (CETP),
a plasma protein that transfers triglycerides from apo-B-con-
taining particles to HDL in exchange for cholesteryl ester (41 ).
It would be expected that transgenic mice expressing both hu-
man apo-B and CETP would have LDL that is more enriched
in cholesteryl ester, but depleted in triglycerides. Alternatively,
the human apo-B100-containing, triglyceride-enriched LDL
may not represent remnants ofVLDL metabolism, but rather
lipoproteins synthesized and secreted de novo as LDL. The
relative availabilities of apo-B and lipid in the hepatocytes of
human apo-B-transgenic mice conceivably could result in the
secretion of nascent triglyceride-rich particles that have LDL
size and density.
The levels of mouse apo-B in transgenic mice expressing
large amounts of human apo-B were not decreased compared
with nontransgenic mice. This result contrasts with observa-
Figure 9. Apo(a) distribu-
Controls tion in plasma of transgenic
h m 1 2 3 4 5 6 7 8 mice. 1 glofplasmafrom
- a Ax an apo(a) transgenic
mouse (lane 1), an apo-B
CL transgenic mouse (lane 2),
and their offspring (lanes
3-8) was loaded onto a 4%
nondenaturing gel. A total
of 0.2 Ml of human plasma
(h) and 1 ul of apo(a) transgenic mouse plasma (im) was included
as controls. After electrophoresis, immunoblotting was performed us-
ing an apo(a)-specific mAb, 1A2. O, apo(a) transgene-positive; @,
human apo-B transgene positive.
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tions in human apo-AI-transgenic mice, where the levels of
mouse apo-AI are markedly decreased (42). In the apo-B-
transgenic mice, the steady-state concentration of the mouse
apo-B must be determined by its rate of secretion from cells
and its clearance from the plasma. As yet, we have not mea-
sured these factors. However, it will be interesting to determine
whether the high human apo-B synthesis and secretion rates
affect the intracellular synthesis and secretion rates for mouse
apo-B, as it is widely assumed that the amount oflipid available
per apo-B molecule may affect the percentage ofnewly synthe-
sized apo-B molecules that are secreted from cells (43).
The ratios of human apo-B100 to human apo-B48 in two
animals with high expression levels (1101 and 1102) were rela-
tively high (- 5:1), whereas the apo-BIOO/apo-B48 ratios
were low in founders with low plasma levels ofapo-B 100. Lusis
et al. (16) previously have reported marked differences in apo-
B100/apo-B48 ratios in different inbred strains of mice, and,
because our founders did not share an identical genetic back-
ground, caution is warranted in ascribing specific explanations
for the different apo-BIOO/apo-B48 ratios. A comprehensive
study involving multiple mice in multiple lines ofhuman apo-
B-transgenic mice will be needed to elucidate the mechanisms
underlying the different apo-B I00/apo-B48 ratios.
Coexpression of human apo-B and apo(a) in transgenic
mice resulted in the production of an Lp(a) particle indistin-
guishable from human Lp(a). This result confirms that the
lack of association of apo(a) with lipoproteins in the apo(a)-
transgenic mice is due to structural differences between mouse
and human apo-B 100. In the double transgenic mice, all ofthe
apo(a) in the plasma was associated with the plasma lipopro-
teins. Interestingly, it appears that expression of human apo-B
increases the concentration of apo(a) in the plasma of the
transgenic mice. Expression of human apo-B may have the
effect of increasing the synthesis and/or secretion ofapo(a) by
hepatocytes. Alternatively, the higher plasma apo(a) concen-
tration in the apo(a) X apo-B mice may be due to a decrease in
the catabolism of Lp(a) when compared with free apo(a).
Studies to elucidate the underlying mechanism responsible for
the increased apo(a) levels in the Lp(a) mice are in progress.
Moreover, the pathologic factors that cause Lp (a) to be athero-
genic can now be studied in these animals.
The human apo-B-transgenic mice reported in this paper
were generated using the insert from a P1 bacteriophage clone,
p158. P1 bacteriophages package 80-100-kb segments of
DNA, making this vector system attractive for recovering the
45-kb apo-B gene (44). We are unaware of a precedent for
generating transgenic mice by microinjecting P1 DNA, al-
though significantly larger fragments of DNA derived from
yeast artificial chromosomes (up to 250 kb) recently have been
microinjected into murine zygotes to generate transgenic mice
(45, 46). Clone p158 may prove to be useful for future studies
ofapo-B structure and function. Sternberg and coworkers have
used transposons to produce random interruptions ofP1 bacte-
riophage clones (47), and they have suggested that the use of
transposons to interrupt exons may be useful for the generation
of a series of truncated proteins for analyzing structure/func-
tion relationships. P1 clones containing transposon-mediated
interruptions ofapo-B exons 26 and 29 might be useful for the
study of apo-B, as these large exons code for important func-
tional regions of the apo-B100 molecule, including the recep-
tor-binding region and the attachment site for human apo(a)
(44, 48).
In future studies, it will be interesting to determine whether
the transgenic mice expressing human apo-B 100 and high lev-
els of LDL cholesterol are susceptible to atherosclerosis. The
studies of Paigen et al. (48, 49) have demonstrated that certain
strains of mice, such as C57BL/6J, develop arterial lesions in
response to a high-fat diet. The susceptibility of C57BL/6J
mice to atherosclerosis depends upon the presence of several
atherosclerosis susceptibility genes, including one, designated
Ath- 1, that is associated with low HDL cholesterol levels in
response to a high-fat diet (48, 50). Because LDL appears to be
particularly atherogenic in many mammalian species, includ-
ing humans, it would be reasonable to speculate that the apo-B-
transgenic mice might be susceptible to atherosclerosis in the
setting of several different genetic backgrounds, perhaps even
genetic backgrounds lacking the previously identified athero-
sclerosis susceptibility genes. It also will be interesting to deter-
mine whether the human apo-B 100 mice will develop sponta-
neous atherosclerosis on a chow diet, as was described recently
for mice lacking apo-E (51, 52).
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